DEFA14A: Novartis to Acquire Avidity Biosciences, Spin-Off Cardiology

Novartis AG will acquire Avidity Biosciences' neuroscience pipeline and RNA platform, while Avidity's early-stage cardiology programs will be spun off into a new independent company.

Summary

• Avidity Biosciences, Inc. (Avidity) has entered into a definitive merger agreement to be acquired by Ajax Acquisition Sub, Inc. (Merger Sub), an indirect wholly-owned subsidiary of Novartis AG (Novartis).
• Avidity will become an indirect wholly-owned subsidiary of Novartis, with the transaction expected to close in the first half of 2026.
• Prior to the merger, Avidity will effect a pre-closing reorganization, spinning off its early-stage precision cardiology programs and certain collaboration agreements into a newly formed Delaware corporation, Bryce Therapeutics, Inc. (to be renamed SpinCo).
• SpinCo will either distribute shares to Avidity stockholders on a pro rata basis (1 share of SpinCo Common Stock per 10 shares of Avidity common stock) or be sold to a third party.
• Novartis will acquire Avidity's neuroscience programs and pipeline, including three late-stage clinical development programs: del-zota, del-desiran, and del-brax, along with its differentiated RNA-targeting delivery platform.
• For the Duchenne Muscular Dystrophy (DMD) program (del-zota), a Biologic License Application (BLA) submission for accelerated approval is planned for 2026, following alignment with the FDA.
• For the Myotonic Dystrophy Type 1 (DM1) program (del-desiran), the 54-week readout from the Phase 3 Harbor Study is expected in the second half of 2026.
• For the Facioscapulohumeral Muscular Dystrophy (FSHD) program (del-brax), topline data from the FORTITUDE biomarker cohort is expected in the second quarter of 2026, and the Phase 3 FORTITUDE-3 readout and global regulatory submissions are expected in 2028.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the definitive merger agreement with a major pharmaceutical company, Novartis, which provides significant resources for Avidity's key neuroscience programs. The concurrent spin-off of early-stage assets also suggests a strategic approach to value creation. While risks inherent in M&A and drug development are noted, the overall tone and strategic implications are favorable for the advancement of Avidity's pipeline.

Positives

• The acquisition by Novartis, a leading global healthcare company, provides significant resources and infrastructure to advance Avidity's late-stage neuroscience programs (del-zota, del-desiran, del-brax) towards commercialization and global expansion.
• The transaction is expected to ensure the continued smooth operation of registrational studies for Avidity's key programs.
• The spin-off of early-stage precision cardiology programs into SpinCo allows for potential independent value realization for these assets.
• Clear regulatory path forward for del-zota (DMD program) with BLA submission planned for 2026 for accelerated approval.
• Novartis's commitment to reaching individuals living with DMD, DM1, and FSHD globally and quickly is highlighted.

Risks

• There is no guarantee that Avidity's investigational products will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time.
• There is no guarantee that Avidity's approach to the discovery and development of product candidates based on its AOC platform will produce any products of commercial value.
• There is no guarantee that the conditions to the closing of the Transactions will be satisfied on the expected timetable or at all, or that the expected benefits or synergies will be achieved.
• The timing of the satisfaction of customary closing conditions, including regulatory approvals and Avidity's stockholder approval, may not occur on acceptable terms or at all.
• Risks and costs are related to the implementation of the separation of SpinCo, including the ability to complete the separation in the anticipated timeframe, or at all, and any changes to the configuration of the businesses included in the separation.
• The sale of certain of SpinCo's assets may be subject to a third-party right of first negotiation.
• There is a risk that competing offers or acquisition proposals will be made.
• The Transactions may cause disruption and impact on Novartis's and/or Avidity's businesses, including relationships with employees, business partners, or governmental entities.
• The Transactions may be more expensive to complete than anticipated.
• Stockholder litigation in connection with the Transactions may result in significant costs of defense, indemnification, and liability.
• The Transactions may cause a diversion of management's attention from ongoing business operations and opportunities.
• Uncertainties are inherent in research and development, including clinical trial results and additional analysis of existing clinical data.
• Regulatory actions or delays or government regulation generally pose risks.

Future Outlook

The transaction is expected to close in the first half of 2026. Avidity's neuroscience programs, including del-zota, del-desiran, and del-brax, are anticipated to continue advancing under Novartis's stewardship. A BLA submission for del-zota is planned for 2026 for accelerated approval. The Phase 3 Harbor Study for del-desiran is expected to have a 54-week readout in the second half of 2026. Topline data from the FORTITUDE biomarker cohort for del-brax is expected in the second quarter of 2026, with Phase 3 FORTITUDE-3 readout and global regulatory submissions anticipated in 2028. The spin-off of early-stage cardiology programs into SpinCo is intended to create a separate, independent company.

Management Comments

• "We will work closely with Novartis to ensure that our registrational studies continue to run smoothly after the transaction closes and are committed to supporting a seamless transition of these programs."
• "As one of the worlds leading global healthcare companies, Novartis is well-positioned to continue advancing del-zota, to commercialization, and we are confident this transaction will support the global expansion of our neuroscience pipeline."
• "Novartis shares our commitment to reaching as many individuals living with DMD amenable to exon-44 skipping as quickly as possible on a global scale."
• "Novartis shares our commitment to reaching as many individuals living with DM1 as quickly as possible on a global scale."
• "Novartis shares our commitment to reaching as many individuals living with FSHD as quickly as possible on a global scale."

Industry Context

This acquisition reflects a broader industry trend where large pharmaceutical companies like Novartis seek to bolster their pipelines and acquire innovative platform technologies from smaller biotech firms. Avidity's RNA-targeting delivery platform and late-stage neuroscience assets represent attractive targets for strategic expansion. The concurrent spin-off of early-stage, non-core assets into an independent entity is also a common strategy to unlock value and allow the acquiring company to focus on the primary strategic assets, while potentially enabling the spun-off entity to pursue its own development and funding pathways.

Comparison to Industry Standards

• The acquisition of a biotech company with a promising late-stage pipeline and a differentiated technology platform by a major pharmaceutical company like Novartis is a standard strategic move in the biopharmaceutical industry, comparable to other large pharma companies acquiring specialized assets to enhance their R&D capabilities and market presence.
• The spin-off of early-stage assets into a new entity (SpinCo) is a common corporate finance strategy, similar to how companies like Pfizer (with Viatris) or Merck (with Organon) have divested non-core businesses to create focused, independent companies, aiming to maximize shareholder value for both the acquiring and divesting entities.

Corporate Governance

Legal Proceedings

• Stockholder litigation in connection with the Transactions may result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• Shareholders of Avidity Biosciences will receive consideration for their shares as part of the acquisition by Novartis and may receive shares in SpinCo as part of the spin-off, subject to the terms of the agreements.
• Employees of Avidity Biosciences involved in neuroscience programs will transition to become part of Novartis, while those involved in early-stage cardiology programs will become part of SpinCo, potentially leading to organizational changes and integration efforts.
• Patients and patient communities (DMD, DM1, FSHD) are expected to benefit from Novartis's resources and global reach, which are anticipated to accelerate the development and commercialization of Avidity's late-stage neuroscience programs and ensure broader access to potential therapies.
• Business partners and governmental entities will experience changes in their relationship with Avidity as it integrates into Novartis and as SpinCo becomes an independent entity, potentially leading to new contractual arrangements or regulatory interactions.

Next Steps

• Avidity and Novartis intend to file relevant documents with the SEC, including a preliminary and definitive proxy statement.
• The definitive proxy statement and proxy card will be delivered to Avidity stockholders in advance of a special meeting relating to the Transactions.
• Avidity stockholders will need to approve the merger.
• Regulatory approvals must be obtained for the transaction to close.
• Avidity will effect a pre-closing reorganization to spin off SpinCo.
• The transaction is expected to close in the first half of 2026.
• BLA submission for del-zota (DMD program) is planned for 2026 for accelerated approval.
• 54-week readout from Phase 3 Harbor Study (del-desiran for DM1) is expected in the second half of 2026.
• Topline data from FORTITUDE biomarker cohort (FSHD program) is expected in the second quarter of 2026.
• Phase 3 FORTITUDE-3 readout and global regulatory submissions for del-brax (FSHD program) are expected in 2028.

Key Dates

Recommendation

The filing details a definitive merger agreement for Avidity Biosciences to be acquired by Novartis, along with a spin-off of certain assets. For existing shareholders, the recommendation is 'hold' as the transaction is expected to close in the first half of 2026, and they will receive consideration for their shares (and potentially SpinCo shares). For new investors, initiating a position at this stage would primarily be an arbitrage play on the deal spread, if any, or a speculative investment in SpinCo, which is not fully detailed in terms of its future capital structure or market listing. Therefore, 'hold' is appropriate for those already invested, awaiting the completion of the announced transaction.

Keywords

Avidity Biosciences, Novartis, Merger, Acquisition, Spin-Off, Neuroscience, RNA-targeting delivery platform, del-zota, del-desiran, del-brax, DMD, DM1, FSHD, Biotechnology, Pharmaceuticals, Clinical Development, Regulatory Approval